Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells (Q45798777)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 April 2012

Language	Label	Description	Also known as
English	Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells	scientific article published on 25 April 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

toll-like receptor

0 references

5

object named as

Steven G Reed

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

author name string

Laura P Schneider

1

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Antoinet J Schoonderwoerd

2

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Magdalini Moutaftsi

3

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Randall F Howard

4

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Esther C de Jong

6

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Marcel B M Teunissen

7

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

language of work or name

0 references

publication date

25 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

30

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

28

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

4216-4224

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Vaccinology at the beginning of the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Tolerogenic dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Toll-like receptors control activation of adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Optimized subunit vaccine protects against experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Cutaneous dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Down-regulation of Toll-like receptor expression in monocyte-derived Langerhans cell-like cells: implications of low-responsiveness to bacterial components in the epidermal Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Cutting edge: virus selectively primes human langerhans cells for CD70 expression promoting CD8+ T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Microbial Compounds Selectively Induce Th1 Cell-Promoting or Th2 Cell-Promoting Dendritic Cells In Vitro with Diverse Th Cell-Polarizing Signals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Keratinocytes and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Cytokines and chemokines in the epidermis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Molecular and cellular signatures of human vaccine adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.04.051

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45798777&oldid=2083244544"